

Table of Contents

List of figures.....	I
List of Tables.....	II
List of Abbreviations.....	III
Abstract.....	VI
Zusammenfassung.....	VII
1 Introduction.....	1
Part A Molybdenum in human health and neurological diseases	1
1.1 Molybdenum and tungsten in biological systems	1
1.2 Molybdenum cofactor and its biosynthesis in humans.....	1
1.3 Human Mo-enzymes.....	4
1.4 Molybdenum cofactor and isolated SO deficiency.....	6
1.4.1 Genetics of MoCD and SOD	6
1.4.2 Clinical presentation in MoCD and SOD	7
1.4.3 Biochemical characterization of MoCD and SOD.....	8
1.4.4 Current state of treatment options for MoCD and SOD	10
1.5 Tungstate as an inducer of MoCD.....	11
Part B Glutamate receptors in neurodegeneration and neurological disorders.....	12
1.6 Glutamate receptors and their functions.....	13
1.6.1 NMDA receptors	14
1.6.2 AMPA receptors.....	14
1.7 NMDARs in excitotoxicity and neurological disorders.....	15
1.8 NMDAR activation and Ca^{2+} deregulation in neuronal death	16
1.9 Calpains in neurodegeneration and neurological diseases.....	17
1.10 NMDAR antagonists in neuroprotection	18

1.11	Cell death pathways in excitotoxic neuronal and brain damage	19
1.11.1	Apoptosis.....	20
1.11.2	Necrosis.....	23
1.11.3	Ferroptosis.....	23
1.12	Aims of work	24
2	Results.....	1
2.1	Cysteine metabolism deregulation in MoCD/SOD	1
2.1.1	Neurotoxic characterization of MoCD-related cysteine metabolites.....	1
2.1.2	Glutamate receptor-mediated toxicity of cysteine metabolites.....	2
2.1.3	Effect of low SSC concentrations on neuronal viability.....	3
2.1.4	Sulfite toxicity is indirectly related to glutamate receptors	5
2.1.5	SSC exhibits toxicity only in neuronal cells	6
2.1.6	Memantine prevents SSC-mediated excitotoxicity in primary neurons	8
2.2	NMDAR activation and Ca ²⁺ -dependent downstream events in SSC-mediated neurotoxicity	9
2.2.1	SSC activates Ca ²⁺ -dependent calpain-1 in primary neurons.....	10
2.2.2	Calpain-1 triggers cleavage of the postsynaptic protein gephyrin at inhibitory synapses in SSC-treated neurons.....	11
2.2.3	Investigation of SSC-induced neurite degeneration.....	13
2.3	Cell death mechanisms activated by SSC in primary neurons	22
2.4	Induction of MoCD in mice by oral tungstate administration	34
2.4.1	Biochemical characterization of tungstate-treated mice	35
2.4.2	Histological characterization of MoCD induced by tungstate	40
2.4.3	Gephyrin is degraded in MoCD mice brain.....	42
2.4.4	Prevention of SSC toxicity and tungstate-induced MoCD by Memantine.....	43
3	Discussion	46
3.1	In vitro characterization of MoCD/SOD-associated neurodegeneration.....	46

3.2	SSC-induced neurite degeneration and cell death in primary neurons	53
3.2.1	Role of SSC in neurite degeneration.....	53
3.2.2	Caspase-dependent cell death in SSC treated neurons.....	55
3.2.3	Caspase-independent cell death in SSC treated neurons	57
3.3	In vivo characterization of the tungsten-induced mice model of Molybdenum Cofactor deficiency and therapeutic implications.....	61
4	Materials and methods.....	66
4.1	Materials.....	66
4.1.1	Chemicals and reagents	66
4.1.2	Caspase and calpain substrates	66
4.1.3	Glutamate receptors blockers	66
4.1.4	Transfection reagents	66
4.1.5	Primary antibodies.....	67
4.1.6	Secondary antibodies	67
4.1.7	Instruments.....	67
4.1.8	Culture media, antibiotics and agar plates	68
4.1.9	Culture media for bacteria.....	68
4.1.10	Culture media for eukaryotic cells	68
4.1.11	Antibiotics	69
4.2	Biological material.....	69
4.2.1	Bacterial strains and vectors	69
4.2.2	Mouse strains	70
4.2.3	Mammalian cell lines.....	70
4.3	Methods.....	71
4.3.1	Biochemical methods.....	71
4.3.2	Molecular biological methods.....	76
4.3.3	Cell biological methods	77

4.3.4	Histological techniques	81
4.4	Animal experiments and treatments.....	82
4.4.1	Tungstate treatment of mice	82
4.4.2	Intraperitoneal memantine injections in mice.....	82
4.4.3	Rotarod performance test	82
4.4.4	Clasping.....	83
4.4.5	Statistical analyses	83
5	References	84
6	Acknowledgement.....	99
7	Curriculum Vitae	100